サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：大うつ病性障害（MDD）市場 - KOLの考察、競合動向、市場分析と予測（2032年）
市場調査レポート
商品コード
1067325

大うつ病性障害（MDD）市場 - KOLの考察、競合動向、市場分析と予測（2032年）

Major Depressive Disorder (MDD) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
出版日: | 発行: Mellalta Meets LLP | ページ情報: 英文 267 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
大うつ病性障害（MDD）市場 - KOLの考察、競合動向、市場分析と予測（2032年）
出版日: 2022年03月25日
発行: Mellalta Meets LLP
ページ情報: 英文 267 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

G7諸国における大うつ病性障害(MDD)の有病者総数は、調査期間（2018年～2032年）において、2032年までに51,356,131人に増加すると予測されています。

推計によると、米国における大うつ病性障害(MDD)の有病者総数は2018年に30,756,221件となりました。今後2032年にかけて大幅なCAGRで拡大すると予測されています。EU5か国の中では、英国が最も症例数が多く、フランス、ドイツ、イタリア、スペインがそれに続いています。日本は、米国、英国に次いで症例数が多いことが報告されています。

当レポートでは、大うつ病性障害（MDD）市場について調査し、市場の概要とともに、大うつ病性障害の疫学、治療動向、2032年までの予測、アンメットニーズと市場の今後の見通しなどを提供しています。

目次

エグゼクティブサマリー

大うつ病性障害（MDD）疾患の背景

  • 大うつ病性障害（MDD）の定義
  • 症状と原因
  • 病態生理学
  • 診断
    • MDD評価ツール
    • 選択されたうつ病スケールの詳細
    • 診断基準
  • 無回答者はTRDを発症するリスクがある

疫学の推定と2032年までの予測

  • 主な調査結果
  • 手法とデータソース
    • 大うつ病性障害（MDD）の国別の一般的な症例（米国、ドイツ、フランス、イタリア、スペイン、英国、および日本）
    • 大うつ病性障害（MDD）の国別の投薬治療症例

大うつ病性障害（MDD）の疫学とモデルパラメーターの主な情報源

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

現在の治療法と医療行為

アンメットニーズ

市販の治療法

  • エスケタミン塩酸塩（Johnson & Johnson）
    • 製品プロファイル
    • 臨床開発
    • 2032年までの売上と市場機会

新たな治療法

大うつ病性障害（MDD）- 償還シナリオ

大うつ病性障害（MDD）- 費用負担と処方調査

将来の治療パラダイム

現在および新たな治療法の年間費用

市場の見通し

  • 主な調査結果
  • 2032年までの国別の市場予測
    • 大うつ病性障害（MDD）のG7市場：2018年～2032年（100万米ドル）
    • 大うつ病性障害（MDD）のG7市場：2018年～2032年（100万米ドル）、治療法別

国別の市場予測

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

市場促進要因と阻害要因

付録

目次
Product Code: MM202046

Current treatment of MDD aims to fully resolve the disease-induced symptoms, to improve the quality of life and functionality in daily life. Despite advancements in MDD treatment and management options, improvements have failed to meet patient desired outcomes. Several emerging therapies such as Dextromethorphan+bupropion/AXS-05 (Axsome Therapeutics), Ansofaxine hydrochloride/LY03005 (Luye Pharma), Zuranolone/SAGE-217 (Biogen Inc./Sage Therapeutics/ Shionogi) are coming up to address the current challenges of MDD patients.

Major depressive disorder (MDD), also referred to as clinical depression, is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function, and vegetative symptoms, such as disturbed sleep or appetite. MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD.

MDD is diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5 criteria. The patient must have at least five of the stated symptoms present during the same two-week period. One of the symptoms must include diminished interest/pleasure or depressed mood. In addition to a psychiatric evaluation, diagnosis of MDD could also include physical and/or blood tests to rule out causes for other conditions such as substance abuse, medical conditions such as diabetes and hypothyroidism, as well as other psychiatric disorders.

Major Depressive Disorder (MDD) Prevalence (Epidemiology)

The total prevalent cases in the G7 countries are anticipated to rise to 51,356,131 by 2032 for the study period (2018-2032).

Major depression is one of the most common mental disorders in the United States. According to the 1-year prevalence data published by National Survey on Drug Use and Health (NSDUH), there were approximately 19.4 million adults in the US that had at least one major depressive episode in the year 2019.

As per estimates, the United States accounted for the highest prevalence of Major Depressive Disorder (MDD) cases in 2018 which was 30,756,221 cases, and is expected to experience a significant rise by 2032 with an impressive CAGR for the study period 2018-2032. Among the EU5, the UK had the highest Major Depressive Disorder (MDD) cases, followed by France, Germany, Italy, and Spain. Japan is reported to have the highest number of cases after the United States and the UK.

Major Depressive Disorder (MDD) Current Market Size & Forecast Trends

The Major depressive disorder (MDD) therapeutics market is expected to increase at a significant rate during the forecast period i.e. 2022-2032. In the year 2022, the market is rapidly evolving and developing at a consistent rate and will depend on the strategies and vision of the major market players. The current MDD treatment market includes tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics.

The increasing prevalence of major depressive disorder, the increasing usage of antidepressants and augmentation medications will drive the MDD market. Additionally, the introduction of new therapies such as Spravato, AXS-05, LY03005, Zuranolone, REL-1017, and others will drive the market growth during the forecast period from 2022-to 2032.

Report Highlights:

  • Major Depressive Disorder (MDD) - Current Market Trends
  • Major Depressive Disorder (MDD) - Current & Forecasted Cases across the G7 Countries
  • Major Depressive Disorder (MDD) - Market Opportunities And Sales Potential for Agents
  • Major Depressive Disorder (MDD) - Patient-based Market Forecast to 2032
  • Major Depressive Disorder (MDD) - Untapped Business Opportunities
  • Major Depressive Disorder (MDD) - Product Positioning Vis-a-vis Competitors' Products
  • Major Depressive Disorder (MDD) - KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Major Depressive Disorder (MDD) Disease Background

  • Major Depressive Disorder (MDD) Definition
  • Symptoms & Causes
  • Pathophysiology
  • Diagnosis
    • MDD Assessment Tools
    • Additional Details on Selected Depression Scales
    • Diagnostic Criteria
  • Primary Nonresponders Are at Risk of Developing TRD

Epidemiology Estimated and Forecast to 2032

  • Key Findings
  • Methods and Data Sources
    • Country Specific Prevalent cases of Major Depressive Disorder (MDD) (US, Germany, France, Italy, Spain, UK, and Japan)
    • Country Specific Drug Treated Cases of Major Depressive Disorder (MDD)

Key Sources for Major Depressive Disorder (MDD) Epidemiology and Model Parameters

  • The United States
    • The United States Prevalent cases of Major Depressive Disorder (MDD)
    • United States Drug Treated Cases of Major Depressive Disorder (MDD)
  • Germany
    • Germany Prevalent cases of Major Depressive Disorder (MDD)
    • Germany Drug Treated Cases of Major Depressive Disorder (MDD)
  • France
    • France Prevalent cases of Major Depressive Disorder (MDD)
    • France Drug Treated Cases of Major Depressive Disorder (MDD)
  • Italy
    • Italy Prevalent cases of Major Depressive Disorder (MDD)
    • Italy Drug Treated Cases of Major Depressive Disorder (MDD)
  • Spain
    • Spain Prevalent cases of Major Depressive Disorder (MDD)
    • Spain Drug Treated Cases of Major Depressive Disorder (MDD)
  • The United Kingdom
    • United Kingdom Prevalent cases of Major Depressive Disorder (MDD)
    • United Kingdom Drug Treated Cases of Major Depressive Disorder (MDD)
  • Japan
    • Japan Prevalent cases of Major Depressive Disorder (MDD)
    • Japan Drug Treated Cases of Major Depressive Disorder (MDD)

Current Therapies and Medical Practice

  • Treatments & Medical Practices
  • Potential Treatment Guidelines/Algorithms
  • Clinical Guidelines for the Treatment of Depression
  • Dosing of medications shown to be effective In treating Major Depressive Disorder (MDD)
  • Marketed treatment for Major Depressive Disorder (MDD)
  • Potential treatments for side effects of antidepressant medications in Major Depressive Disorder (MDD)

Unmet Needs

Marketed Therapies

  • Esketamine hydrochloride (Johnson & Johnson)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032

Emerging Therapies

  • Pipeline Overview
  • Therapeutic Developments Pipeline for Major Depressive Disorder (MDD)
    • Product Analysis
  • AXS-05 (Axsome Therapeutics Inc.)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • LY03005 (Luye Pharma)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Zuranolone (Biogen Inc./Sage Therapeutics/Shionogi)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Cariprazine (Gedeon Richter Plc./Abbvie)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Caplyta (Intra-Cellular Therapies Inc.)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • REL-1017 (Relmada Therapeutics Inc.)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Seltorexant (Minerva Neurosciences/Janssen/Royalty Pharma)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • PRAX-114 (Praxis Precision Medicines Inc.)
    • Product Profile
    • Clinical Development
  • SPL026 (Small Pharma)
    • Product Profile
    • Clinical Development
  • SLS-002 (Seelos Therapeutics Inc.)
    • Product Profile
    • Clinical Development
  • Psilocybin (Usona Institute/The Emmes Company/Signant Health)
    • Product Profile
    • Clinical Development
  • PH10 (Pherin Pharmaceuticals/VistaGen Therapeutics)
    • Product Profile
  • AV-101 (VistaGen Therapeutics Inc.)
    • Product Profile
    • Clinical Development
  • Other Emerging Drugs For Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)- Reimbursement Scenario

Major Depressive Disorder (MDD)- Cost Burden & Prescriptions survey

Future Treatment Paradigm

  • Major Depressive Disorder (MDD) Competitor Landscape and Approvals Anticipated
  • Future Treatment Algorithms and Competitor Positioning
  • Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

  • Key Findings
  • Country-Specific Market Forecast to 2032
    • G7 total Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • G7 total Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)

Market Forecast by Country

  • The United States
    • United States Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • United States Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Germany
    • Germany Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Germany Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • France
    • France Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • France Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Italy
    • Italy Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Italy Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Spain
    • Spain Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Spain Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • The United Kingdom
    • United Kingdom Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • United Kingdom Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Japan
    • Japan Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Japan Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Major Depressive Disorder (MDD)?
  • What Factors Are Constraining the Market for Major Depressive Disorder (MDD)?

Appendix

  • About Mellalta Meets